NCT00455260已完成1 期
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study, to Assess Tolerability, Safety, Pharmacokinetic and Pharmacodynamic Profiles of hGH-ViaDerm™ System in Adult Subjects With Growth Hormone Deficiency
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 60
- 主要终点
- Laboratory values
研究概览
简要总结
This study aims to examine the safety, tolerability and pharmacokinetics of transdermal delivery of human Growth Hormone (hGH or somatropin) using the ViaDerm device in adult patients with Growth Hormone Deficiency Syndrome.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 20 Years 至 60 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Ages Eligible for Study: 20 Years - 60 Years, Genders Eligible for Study: Both
- •Clinical diagnosis of Adult Growth Hormone Deficiency (AGHD) meeting one of the following criteria:
- •Three or more additional pituitary hormone deficiencies, based on well documented medical history from up to 10 years prior to screening, and/or serum IGF-1 levels below 2 SD from normal level, measured up to 4 months prior to screening.
- •One or two additional pituitary hormone deficiencies with one GH stimulating test performed within 10 years prior to screening: Insulin Tolerance test with GH levels less than 5.1 µg/L or ARG-GHRH with GH levels less than 4.1 µg/L.
- •Isolated GH deficient subjects with two well-documented GH stimulating tests performed within 10 years prior to screening. Insulin Tolerance test with GH levels less than 5.1 µg/L or ARG-GHRH with GH levels less than 4.1 µg/L.
- •In childhood onset AGHD, confirmation of GHD following attainment of full height.
- •Subjects using hormone replacement therapy for additional pituitary deficits must be on an optimized treatment regimen for at least three months prior to screening.
- •Willing and able to provide written informed consent prior to performing any study procedures.
排除标准
- •GH therapy within one month prior to study entry.
- •For female subjects: pregnancy or lactation or use of oral contraception or unacceptable method of contraception throughout the study.
- •Active acromegaly in the last 5 years.
- •Carpal tunnel syndrome.
- •Prader-Willi syndrome.
- •Active Cushing's syndrome within the last 12 months.
- •Non-compliance for upper arm SC injection or patch application.
- •Skin color or tattoo that would not enable detection of erythema.
- •Upper extremities with skin marks, bruises, cuts, abrasions on the upper arm.
- •Dense and dark hair growth on upper extremities.
- •History of skin hypersensitivity and/or allergies.
- •Known hypersensitivity to somatropin or mannitol
- •Evidence of active malignancy.
- •Previous use of chemotherapy, immunosuppressive or radiation therapy, except for treatment of pituitary disease.
- •Serum glucose (fasting) > 126 mg/dl.
- •Known or suspected HIV-positive subjects or subjects with advanced diseases such as AIDS, Hepatitis C, Hepatitis B or tuberculosis.
- •Subjects who, based on the investigator's judgment, have a clinically significant or unstable medical or surgical condition that may preclude safe and complete study participation. Conditions may include cardiovascular, vascular, pulmonary, hepatic, renal, or neurological disease, as determined by medical history, physical examination, laboratory tests or ECG.
- •BMI < 19 and ≥ 35 kg/m
- •Weight reducing drugs or appetite suppressants.
- •Estrogen replacement therapy except transdermal patch.
- •Any psychological condition which may influence the compliance with the study requirements.
- •Unstabilized antidepressant or antipsychotic medication therapy within 2 months prior to screening.
- •Subjects with a known history of alcohol abuse.
- •Subjects who received blood or plasma derivatives in the three months preceding screening.
- •Subjects who donated blood in the preceding three months of screening or intend to make a blood donation during the study, or within the three months following the study completion.
- •Subjects who have participated in another clinical study of any kind (drug or device) in the one month prior to screening.
- •Subjects who, in the judgment of the investigator, are likely to be non-compliant or uncooperative during the study.
结局指标
主要结局
Laboratory values
时间窗: 36 days
Vital signs
时间窗: 36 days
ECG
时间窗: 36 days
Patch application site reaction: Skin irritation- erythema, edema
时间窗: 36 days
AE
时间窗: 36 days
Patch application site reaction: Pain - Visual Analogue Scale
时间窗: 36 days
Proportion of subjects (%) who discontinue the study
时间窗: 36 days
Proportion of subjects (%) who discontinue the study due to AEs
时间窗: 36 days
Pharmacokinetics: Somatropin exposure including Cmax, Tmax, AUC, AUC, Ke, and T1/2.
时间窗: 36 days
Pharmacodynamics: Human IGF-1 levels and AUC.
时间窗: 36 days
次要结局
未报告次要终点
研究者
相似试验
终止
2 期
Safety, Pharmacokinetics, and Efficacy of Subcutaneous Isatuximab in Adults With Warm Autoimmune Hemolytic Anemia (wAIHA)Warm Autoimmune Hemolytic Anemia (wAIHA)NCT04661033Sanofi8
已完成
3 期
A Study of the Safety and Efficacy of Golimumab in Subjects With Active Ankylosing SpondylitisSpondylitis, AnkylosingNCT00265083Centocor, Inc.356
已完成
3 期
Study to Evaluate the Clinical Efficacy and Safety of Subcutaneously Administered C1 Esterase Inhibitor for the Prevention of Angioedema Attacks in Adolescents and Adults With Hereditary AngioedemaHereditary Angioedema (HAE)NCT02584959Shire75
终止
1 期
Study of KHK 4323 in Healthy Volunteers and Subjects With Atopic DermatitisAtopic DermatitisNCT03846466Kyowa Kirin Co., Ltd.5
已完成
3 期
Safety Study of ATX-101 (Deoxycholic Acid) in Subjects With Mild or Extreme Fullness of Submental FatModerate to Severe Convexity of Submental FatSafetyEfficacyNCT02035267Kythera Biopharmaceuticals93